Clinical Trials for Unresectable Hepatocellular Carcinoma

Find clinical trials for unresectable hepatocellular carcinoma. Discover research opportunities and treatment options in your area.

30 Active Trials Found

Showing 30 trials on this page

Page 2 of 2

TACE Plus Camrelizumab and Apatinib for Unresectable Hepatocellular Carcinoma

NCT ID: NCT06485466

This clinical trial is investigating a new treatment approach for patients with unresectable hepatocellular carcinoma (HCC), a type of liver cancer that cannot be surgically removed. The study is l...

Recruiting

Phase: PHASE3 Type: interventional Locations: Chengdu, Sichuan, China

Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors

NCT ID: NCT05269381

This clinical trial is investigating a new type of personalized vaccine designed to help the immune system recognize and attack advanced solid tumors, which are cancers that have spread beyond thei...

Recruiting

Phase: PHASE1 Type: interventional Locations: Jacksonville, Florida, United States

Anti-PD-1/PD-L1 Combined With Anti-angiogenic Agents as First-line Treatment for Unresectable HCC

NCT ID: NCT06360042

This clinical trial is exploring new treatment options for patients with unresectable hepatocellular carcinoma (HCC), which is a type of liver cancer that cannot be surgically removed. The study is...

Recruiting

Phase: PHASE2 Type: interventional Locations: Beijing, Beijing, China

Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer

NCT ID: NCT05168163

This clinical trial is studying a new treatment approach for patients with liver cancer that cannot be surgically removed, has spread to nearby tissues, or has metastasized to other parts of the bo...

Recruiting

Phase: PHASE2 Type: interventional Locations: Durham, North Carolina, United States, Milwaukee, Wisconsin, United States +15 more

A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + Bevacizumab

NCT ID: NCT05199285

This clinical trial is investigating the combination of two immunotherapy drugs, nivolumab and ipilimumab, to see if they can help shrink tumors in patients with advanced liver cancer. This study i...

Recruiting

Phase: PHASE2 Type: interventional Locations: Atlanta, Georgia, United States, New Brunswick, New Jersey, United States +4 more

DEB-TACE+HAIC vs. HAIC for Large HCC

NCT ID: NCT05263219

This clinical trial, known as DEB-TACE+HAIC vs. HAIC, is studying a new treatment approach for patients with large unresectable hepatocellular carcinoma (HCC), which is a type of liver cancer that ...

Recruiting

Phase: PHASE3 Type: interventional Locations: Guangzhou, Guangdong, China

Phase 2 Study of SBRT Plus Tislelizumab and Regorafenib in Unresectable or Oligometastatic HCC

NCT ID: NCT05917431

This clinical trial is investigating a treatment approach for patients with unresectable hepatocellular carcinoma (HCC), which means the cancer cannot be surgically removed, or those with a limited...

Recruiting

Phase: PHASE2 Type: interventional Locations: Beijing, Beijing, China

Phase Ib/II Trial of Combining Pembrolizumab and Lenvatinib With SBRT for HCC Patients With Portal Vein Thrombosis.

NCT ID: NCT05286320

This clinical trial is looking at a new combination treatment for patients with a type of liver cancer called hepatocellular carcinoma (HCC) who also have a blockage in the portal vein, known as po...

Not yet recruiting

Phase: PHASE1 Type: interventional Locations: Taipei City, , Taiwan, Taipei City, Taiawn, Taiwan +1 more

Donafenib Plus Sintilimab in Combination With TACE in Patients With Unresectable Hepatocellular Carcinoma

NCT ID: NCT05507632

This clinical trial is studying a new treatment approach for patients with unresectable hepatocellular carcinoma (HCC), which is a type of liver cancer that cannot be surgically removed. The trial ...

Not yet recruiting

Phase: PHASE2 Type: interventional

Camrelizumab in Patients With Unresectable Hepatocellular Carcinoma

NCT ID: NCT04947956

This clinical trial is studying a medication called camrelizumab for patients with unresectable hepatocellular carcinoma (HCC), which is a type of liver cancer that cannot be surgically removed. HC...

Not yet recruiting

Type: observational

Related Conditions

Breast Cancer View clinical trials → Stroke View clinical trials → Obesity View clinical trials → Cancer View clinical trials → Healthy View clinical trials → Prostate Cancer View clinical trials →

Search All Trials Browse All Conditions